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Abstract
Atypical models of experimental autoimmune encephalomyelitis (EAE) are advantageous in that the heterogeneity of
clinical signs appears more reflective of those in multiple sclerosis (MS). Conversely, models of classical EAE feature
stereotypic progression of an ascending flaccid paralysis that is not a characteristic of MS. The study of atypical EAE however
has been limited due to the relative lack of suitable models that feature reliable disease incidence and severity, excepting
mice deficient in gamma-interferon signaling pathways. In this study, atypical EAE was induced in Lewis rats, and a related
approach was effective for induction of an unusual neurologic syndrome in a cynomolgus macaque. Lewis rats were
immunized with the rat immunoglobulin variable (IgV)-related extracellular domain of myelin oligodendrocyte glycoprotein
(IgV-MOG) in complete Freund’s adjuvant (CFA) followed by one or more injections of rat IgV-MOG in incomplete Freund’s
adjuvant (IFA). The resulting disease was marked by torticollis, unilateral rigid paralysis, forelimb weakness, and high titers of
anti-MOG antibody against conformational epitopes of MOG, as well as other signs of atypical EAE. A similar strategy elicited
a distinct atypical form of EAE in a cynomolgus macaque. By day 36 in the monkey, titers of IgG against conformational
epitopes of extracellular MOG were evident, and on day 201, the macaque had an abrupt onset of an unusual form of EAE
that included a pronounced arousal-dependent, transient myotonia. The disease persisted for 6–7 weeks and was marked
by a gradual, consistent improvement and an eventual full recovery without recurrence. These data indicate that one or
more boosters of IgV-MOG in IFA represent a key variable for induction of atypical or unusual forms of EAE in rat and
Macaca species. These studies also reveal a close correlation between humoral immunity against conformational epitopes
of MOG, extended confluent demyelinating plaques in spinal cord and brainstem, and atypical disease induction.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the central nervous system (CNS) characterized by
focal inflammatory lesions and demyelinating plaques in periven-
tricular and perivascular regions of the CNS [1–3]. MS is a
clinically heterogeneous disease with substantial variability in both
clinical presentation and disease progression. Experimental
autoimmune encephalomyelitis (EAE) is a common model of
MS used to investigate immunopathogenesis and test potential
therapeutics [4–6]. Research in EAE has focused on ‘classical’
models in which disease progression is marked by a stereotypical
ascending flaccid paralysis. Rats afflicted with classical EAE
initially present with flaccid paralysis of the distal tail followed by
an anterior progression over the next 1–3 days culminating in a
symmetric paralysis of both hindlimbs. Classical disease courses
are monophasic, relapsing-remitting, or chronic-progressive de-
pending on the rodent strain and immunizing antigen, with focal
mononuclear inflammatory lesions observed in the spinal cord and
brainstem. However, a stereotypical ascending flaccid paralysis,
which is the defining clinical hallmark of classical EAE, is seldom
observed in MS.
Variants of EAE that feature ‘atypical’ clinical signs may be
more representative of disease heterogeneity in MS. Atypical
forms of EAE are marked by a lack of ascending paralysis,
irregular disease progression, and substantial inter-animal hetero-
geneity in onset and presentation of clinical signs. Atypical EAE in
mice and rats is often marked by: (a) axial-rotary torticollis/head-
tilt (vertigo), (b) rigid or spastic asymmetric paralysis or unilateral
forelimb and/or hindlimb weakness, (c) unilateral ataxia, (d)
paralysis without tail involvement, (e) uneven or sporadic disease
progression, and (f) in some models by a delayed onset and a
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e110048
prolonged non-resolving time course [7–11]. The torticollis often
progresses to the extent that the rodent will continually rotate
about the body axis, presumably in an effort to right itself, possibly
reflecting a sensory deficit of the vestibular control centers. Unlike
classical forms of EAE, several studies have noted that atypical
disease features an abundance of inflammatory lesions in the brain
including the midbrain, cortex, and cerebellum.
Although atypical EAE may more closely reflect the diverse
pathogenic processes of MS, the focus on classical EAE rather
than atypical EAE is primarily due to a lack of models with
consistent clinical signs of atypical disease in wildtype animals. The
most robust models of atypical EAE are in mouse strains
genetically deficient in the interferon gamma (IFN-c) signaling
pathway [12] but these mice have abnormal immune systems that
cannot be used to accurately model MS. Atypical EAE in
susceptible wildtype mouse strains has a variable incidence. Some
mice initially develop atypical EAE but spontaneously transition to
an ascending flaccid paralysis, whereas other mice of the same
cohort solely develop classical disease [8–10]. Thus, there is a need
for atypical models of EAE that are inducible and feature reliable
and uniform incidence of severe atypical disease.
EAE in the Lewis rat is a widely used model for MS. Lewis rats
given a single immunization with myelin basic protein in complete
Freund’s adjuvant (CFA) exhibit a classical monophasic course of
EAE marked by 3–5 days of tail and hind-limb paralysis followed
by complete spontaneous remission [13]. Immunization of Lewis
rats with myelin oligodendrocyte glycoprotein (MOG)-derived
peptides or proteins in CFA causes a mild monophasic form of
EAE [14]. MOG is present on the outer-surface of CNS myelin
and is a quantitatively minor protein component of the myelin
sheath. MOG is a target for demyelinating antibody (Ab) in
humans and non-human primates (NHP) and causes EAE in NHP
[15–22]. MOG also causes EAE in mice in spontaneous and
induced disease models by Ab-dependent and independent
mechanisms [22–25]. In contrast, NHP often exhibit a hyperacute
neurologic disease marked by hemorrhagic/necrotic lesions in the
brain that resembles fulminant forms of MS [18–21]. Overall,
development of suitable EAE models in NHP has been problem-
atic due to excessive susceptibility of NHP to EAE, aggressive
severe disease, rapid progression to humane endpoints, neutro-
philic and/or hemorrhagic inflammatory CNS lesions, and an
insufficient time window for therapeutic intervention.
An atypical model of EAE in the Lewis rat and NHP would
represent an important advance because such a model would
enable vetting of novel therapeutic interventions that may have
more direct relevance for drug development in MS. Herein, we
show that Lewis rats immunized with the immunoglobulin
variable (IgV)-related extracellular domain of MOG (IgV-MOG)
in CFA and subsequently boosted with IgV-MOG in incomplete
Freund’s adjuvant (IFA) exhibited high incidence of a severe,
chronic course of atypical EAE. A similar immunization/boost
strategy via repeated administration of IgV-MOG in IFA also
induced a self-limited bout of nonclassical EAE in a cynomolgus
macaque. This study thereby introduces a unique protocol to
induce atypical/non-classical EAE as an advancement in model
development for MS.
Materials and Methods
Ethics statement
Lewis rats (Rattus norvegicus) and the cynomolgus macaque
(Macaca fascicularis) were housed at East Carolina University.
Animal care and use were performed in accordance with approved
animal use protocols for Lewis rats (K144b), the cynomolgus
macaque (K154), and institutional guidelines of the East Carolina
University’s Institutional Animal Care and Use Committee. All
injections were given to rats and the cynomolgus macaque while
under isoflurane anesthesia (Abbott Laboratories, Chicago, IL).
During expression of EAE, rats were monitored twice per day, and
the NHP was monitored three times per day.
A colony of cynomolgus macaques (Macaca fascicularis) born
between 1998 and 2006 was maintained at East Carolina
University. Twice annually, the colony was monitored for simian
retroviruses, simian T-cell leukemia virus, herpes B virus, and
simian immunodeficiency virus via multiplexed fluorometric
immunoassays. In addition, macaques were tuberculin-tested
intradermally. Annually, the colony underwent fecal analysis for
parasites and fecal culture for Shigella, Campylobacter, and
Salmonella species. The macaques had ad libitum access to water
via an automated watering device, were fed chow twice daily
(LabDiet Monkey Diet 5038, Purina Laboratory, St Louis, MO),
and were supplemented daily with fruits and vegetables. The light
cycle was maintained on a 12:12-hour light:dark cycle. Macaques
were housed indoors in same-sex groups of 2 to 6 macaques in
stainless steel caging that included gang-caging and vertical
tunnels connecting upper and lower batteries to provide vertical
mobility and voluntary visual and physical separation from
cagemates. Temporary separation of macaques for experimental
monitoring or clinical interventions was accomplished by using
screens that maintained visual and tactile connection whenever
feasible. The fresh-air supply to rooms housing macaques was
filtered at MERV 8 (,3 to 10 mm particle diameter) to minimize
exposure to environmental allergens. The macaques were assigned
to IACUC-approved protocols and were maintained in accor-
dance with the USDA Animal Welfare Act and regulations and
the Guide for the Care and Use of Laboratory Animals. The animal
care and use program at East Carolina University is USDA-
registered, maintains a Public Health Services Assurance, and is
fully accredited by AAALAC.
The subject in this study was initially housed with a cage-mate.
Daily enrichments consisted of various items within the enclosure
(ropes, tennis balls, stuffed toys, etc.), radio music, and a variety of
fresh fruits, vegetables, seeds, and cereals for snacking. Other
enrichment included access to a water tub for swimming activities
and television and/or movies. All antigen injections were in IFA
and were given to the cynomolgus macaque while under isoflurane
anesthesia. The subject was directly observed once per day until
disease onset and then at least three times per day in 30 minute
sessions during overt disease. In addition, a web camera was
placed in the room for remote monitoring at any time by the
veterinary staff and investigators. Upon onset of EAE, the subject
was housed separately in caging that included at least 4 feet of
vertical height and 8 square feet of floor space. The subject had
voluntary visual contact with other animals within the room.
Hydration was supplemented with fluids such as Gatorade or
Kool-Aid. Fruit and vegetable enrichments were given at least
twice per diem. All measures were taken to ensure the safety and
well-being of the subject. After 730 days of observation and 482
days after spontaneous recovery from EAE, the subject was
euthanized with intravenous sodium pentobarbital (100 mg/kg)
following anesthesia with intramuscular Telazol (4 mg/kg).
Tissues were collected and analyzed following a complete
necropsy.
Expression systems for Full Length MOG and IgV-MOG
RNA was purified from rat or macaca CNS tissue by use of the
TRizol Reagent (Life Technologies, Carlsbad, CA). Four expres-
sion vectors were constructed for this study. Rat and macaca
IgV-MOG Elicits Atypical EAE
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cDNA encoding the IgV domain of MOG and full length MOG
protein were amplified from total CNS RNA by RT-PCR. Rat
and macaca DNA species encoding the IgV-MOG domain were
inserted into the pQE-40 prokaryotic expression vector (Qiagen,
Valencia, CA), whereas the rat and macaca DNA sequences
encoding the full length proteins were inserted into the pIRES2-
AcGFP1 mammalian expression vector (Clontech, Mountain
View, CA). Directional restriction site-free overlap extension was
used to insert the respective DNA into the expression vectors.
The pQE-40 recombinant vectors were used to express rat and
macaca IgV-MOG as inclusion bodies in the M15[pREP4] strain
of E. coli. The N-terminus of the protein (MRGSHHHHHHGSGI)
was encoded by the vector. The adjoining sequence represented the
rat or macaca 1–123 amino acid sequence of IgV-MOG that
replaced a vector-encoded murine dihydrofolate reductase sequence.
The IgV-MOG sequence did not include the signal sequence and
spanned amino acid positions from GQFRVIGP…¥VEDPFYWIN
for the rat protein and GQFRVIGP……VEDPFYWVS for the
macaca protein. The 6xhistidine N-terminal sequence was used as
an affinity tag for purification of the protein.
The recombinant pIRES2-AcGFP1 expression vectors were
engineered to encode full length rat and macaca MOG as
transmembrane surface proteins. The full length proteins included
the native MOG signal sequences to direct export through the
Golgi apparatus to the cell surface so that the recombinant
proteins would have the predicted patterns of N-linked glycosyl-
ation. These expression vectors were transfected into 293F human
embryonic kidney cells (HEK) by use of TurboFect transfection
reagent (Thermo Fisher Scientific, Waltham, MA). Stable lines
were obtained by drug selection and use of a Becton Dickinson
FACSVantage cell sorter (Franklin Lakes, NJ) to isolate cells that
expressed high levels of green fluorescent protein (GFP) and cell
surface MOG.
Expression and purification of IgV-MOG
Recombinant rat and macaca IgV-MOG proteins were purified
from transformed E. coli M15[pREP4] cells after 3–4 hours of
induction with isopropyl b-D-1-thiogalactopyranoside. Cell pellets
were lysed in 8 M urea (with 100 mM NaH2PO4, 10 mM Tris-Cl,
pH 8.0). Proteins were purified by affinity chromatography on Ni-
NTA agarose columns (Qiagen, Valencia, CA). After elution,
proteins were refolded at 500 mg/ml by stepwise dialysis in buffer
A (4 M urea, 50 mM glycine, 15.6 mM NaOH, 10% w/v sucrose,
1 mM EDTA, 1 mM reduced glutathione, 100 mM oxidized
glutathione at pH 9.6), buffer B (60 mM ethanolamine, 10% w/v
sucrose, 1 mM EDTA, 100 mM reduced glutathione, and 10 mM
oxidized glutathione at pH 9.6), and finally in 20 mM sodium
acetate buffer (pH 4.0). Alternatively, protein preparations were
reduced prior to folding via incubation with 20 mM TCEP-HCl
(EMD, Billerica, MA) and dialyzed against 4 M urea (with
100 mM NaH2PO4, 10 mM Tris-Cl, pH 8.0) to remove the
TCEP-HCl. Proteins were then refolded at approximately
500 mg/ml by stepwise dialysis against buffer A, buffer B, and
ultrapure ‘Milli-Q’ H2O. Soluble preparations were concentrated
in Amicon Ultra-15 centrifugal filter devices (MilliPore, Billarica,
MA). Protein quantity was assessed by absorbance at 280 nm and
purity was assessed by SDS-PAGE. Protein preparations were
aliquoted and stored frozen at 280uC.
Induction and measurement of EAE in rat and Macaca
species
A synthetic peptide representing the dominant encephalitogenic
sequence of guinea pig myelin basic protein (GP69-88) (Y-G-S-L-
P-Q-K-S-Q-R-S-Q-D-E-N-P-V-V-H-F) was purchased from
Quality Controlled Biologicals, Inc. (Hopkinton, MA). To elicit
EAE, Lewis rats were injected with an emulsion containing
designated doses of GP69-88 and/or rat IgV-MOG in CFA. The
CFA emulsion was prepared by mixing 1 part antigen in buffered
saline and 1 part CFA (4 mg/ml of heat killed Mycobacterium
tuberculosis H37Ra, Difco, Franklin Lakes, NJ per 1 ml of IFA)
followed by sonication on ice until the emulsion was thick, viscous,
and stable in water. The emulsion contained a final dose of 200 mg
of heat killed Mycobacterium tuberculosis in 0.1 ml volume which
was injected as two 0.05 ml subcutaneous injections on either side
of the base of the tail for each rat. Where indicated, subsequent
booster immunizations consisted of 200 mg rat IgV-MOG in IFA.
All immunized rats were weighed and scored daily for classical or
atypical signs of EAE and were observed twice daily during active
disease. The following scale was used to score classical EAE: no
clinical disease = 0; paralysis in the distal tail = 0.25; limp tail = 0.5;
ataxia = 1.0; hindlimb paresis = 2.0; full hindlimb paralysis = 3.0.
Ataxia was scored as an uneven or wobbly gait. Hind leg paresis
was scored as the retention of some voluntary ambulatory
movement in the hind limbs but without the ability to ambulate
upright. Rats exhibiting atypical EAE were scored by the following
scale: no overt clinical signs = 0; forelimb weakness without
hindlimb involvement = 0.25; ataxia without flaccid paralysis of
the tail = 0.5; rigid asymmetric extension of a hindlimb or forelimb
(as opposed to flaccid paralysis) = 1.0; disequilibrium with mild
torticollis or tail rigidity = 2.0; continuous torticollis, axial rotation,
or abnormal bodily contortions = 3.0. Forelimb weakness was
assessed by the animal’s ability to grasp the wire cage top and
maintain hold against slight pull. Mild torticollis was scored as a
slight tilt of the head to either side. Severe torticollis was marked
by involuntary body rotation along the longitudinal axis.
Abnormal bodily contortions were defined as asymmetrical
bilateral extension of the hindlimbs and/or corkscrew tail.
The cynomolgus macaque received subcutaneous immuniza-
tions with an emulsion containing 500 mg rat IgV-MOG in IFA on
days 0 and 22 together with additional booster immunizations in
IFA containing a mixture of 500 mg rat IgV-MOG and 500 mg
macaca IgV-MOG on days 36, 63, and 93 (Table 1). Each
immunization or booster was given in a total volume of 0.4 mL as
4 separate 0.1 ml injections in each of the axillary and inguinal
areas. The subject was scored at least once daily over the 2-year
observation period and three times daily during the phase of active
disease. The following clinical scale was used to score EAE in the
NHP: loss of finger dexterity, dyscoordination of hand(s)/feet, or
repetitive mastication movements, droop in facial features,
guarded ambulatory movement, pronounced lack of voluntary
movement = 0.5; gross motor dyscoordination during ambulation,
apparent sensory disturbance, transient myotonia with uncon-
trolled balling of hand or foot = 1.0; gross unilateral or bilateral
weakness, transient myotonia with full limb involvement including
rigid extension paralysis or falling to one side = 2.0; hemi- or
paraparesis = 2.5; hemi- or paraplegia = 3.0; quadriplegia and/or
somnolence = 4.0; moribund= 5.0.
Histological assessment of EAE in rats
After humane euthanasia, the spinal column and brain were
removed and were fixed in 10% neutral buffered formalin. Spinal
cords were removed from the spinal column after fixation.
Standard sections were prepared for each CNS. Standard
longitudinal sections were prepared of the entire spinal cord
(cervical, thoracic, lumbar, and sacral cord). Standard sections of
the brain and brainstem were visualized as an obliquely angled
section of the horizontal plane that spanned the prefrontal cortex
through the base of the brainstem. Standard sections of the brain
IgV-MOG Elicits Atypical EAE
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and cerebellum were visualized as an obliquely angled section of
the horizontal plane that spanned the prefrontal cortex through
the posterior lobe of the cerebellum. Sections were stained with
hematoxylin and eosin to visualize perivascular mononuclear
infiltration or Luxol Fast Blue to visualize demyelination. Regions
of demyelination were defined by areas lacking the Luxol Fast Blue
myelin stain. CNS lesions were scored by a blinded observer.
Sections were imaged with a Leica DFC420C digital camera
connected to a Leica DM400B microscope at 256 or 4006 total
magnification.
Fluorescent-linked immunosorbent assay analyses
Blood was collected from the tail vein of Lewis rats under
isoflurane anesthesia. Similarly, macaca blood was collected from
the femoral vein. Serum was harvested after clotting by
centrifugation and was stored in aliquots frozen at 280uC.
Adherent HEK cells were grown to 60–80% confluence and
incubated with a release buffer (2 mM EDTA and 0.5% bovine
serum albumin in phosphate buffered saline) for 5–10 minutes.
HEK cells were then dispensed into flow tubes at 26105 cells/
tube. HEK that did or did not express full length rat or macaca
MOG were incubated with 0.2%–2% titrations (unless designated
otherwise) of control serum, immune rat serum, or immune
macaca serum. After an initial incubation of 45 minutes, HEK
were washed 3 times in Hank’s buffered salt solution supplemented
with 1% heat inactivated fetal bovine serum. Rat Ab specific for
conformational epitopes of MOG were detected by staining with a
secondary allophycocyanin-conjugated goat-anti-rat IgG/M Ab
(Southern Biotech, Birmingham, AL) followed by 3 more washes.
Binding of macaca anti-MOG immune serum to HEK was
detected by use of allophycocyanin-conjugated goat-anti-monkey
IgG/M/A, IgG, IgA, or IgM Ab (Brookwood Medical Center,
Birmingham, AL). Data were collected by use of a Becton-
Dickinson LSRII flow cytometer (Franklin Lakes, NJ) and
analyzed by use of FlowJo software (FlowJo LLC, Ashland, OR).
An alternative plate-based staining assay was also devised to
measure anti-MOG Ab binding. Adherent HEK cells were grown
to 60–80% confluence in 96 well microtiter plates. The wells were
incubated with designated titrations of anti-MOG sera for
45 minutes, followed by three washes, an incubation with the
secondary reagent, another three washes, a brief exposure to the
release buffer followed by neutralization of the EDTA with
complete RPMI media (containing 10% heat-inactivated fetal
bovine serum), and flow analysis on the Becton-Dickenson LSRII
flow cytometer with the High Sample Throughput 96 well plate
reader. Staining protocols for both tube and plate assays were
performed at 4uC.
Results
IgV-MOG induces atypical EAE in Lewis rats
Previous studies have shown that Lewis rats immunized with
GP69-88 in CFA exhibit an acute monophasic course of classical
EAE [13,26]. After spontaneous recovery, rats remain healthy and
typically do not exhibit a subsequent relapse of severe EAE.
Conversely, immunization of Lewis rats with IgV-MOG induces a
mild episode of classical EAE associated with focal demyelination
[14]. Pathogenesis appeared to reflect synergy between a weak
encephalitogenic MOG-specific T cell response and generation of
a MOG-specific, demyelinating Ab. Given that the dominant
encephalitogenic region of myelin basic protein elicits strong
encephalitogenic T cell responses and that conformational
epitopes of MOG elicit demyelinating Ab, preliminary studies
were performed to assess the EAE phenotype in Lewis rats co-
immunized with both GP69-88 and IgV-MOG (Figure 1).
Immunization of seven Lewis rats with 25 mg GP69-88 and
50 mg rat IgV-MOG emulsified in CFA caused a monophasic
episode of EAE marked by an ascending flaccid paralysis followed
in 3–5 days by a full and spontaneous recovery. This initial bout
was essentially identical to what is typically observed in myelin
basic protein-induced classical EAE. Following recovery, subse-
quent boosts of rat IgV-MOG in IFA on days 45 and 85 caused a
second bout of chronic ‘atypical’ EAE marked by unusual clinical
signs: forelimb weakness without hindlimb involvement, ataxia
without flaccid paralysis of the tail, dystonia, rigid asymmetric
extension of a hindlimb or forelimb (as opposed to flaccid
paralysis), and/or vertigo/disequilibrium and torticollis. The
incidence of both classical and atypical disease was 100% (7 of 7
rats), yet the day of onset for atypical EAE was not uniform and
the rate of disease progression was varied (Figure 1). Rats were
humanely euthanized for weight loss greater than 25%, extreme
dehydration for more than 48 hours, or at the conclusion of the
experiment on day 125. Despite inconsistencies in the kinetics of
disease, these data suggested that a severe course of atypical EAE
could be reliably elicited in Lewis rats.
To address the minimal immunization requirements to elicit
atypical EAE, two groups of rats (n = 12 each) received a primary
Table 1. The immunization and serum collection schedule for the cynomolgus macaque.
Day Immunization parametersa
0 Serum collection Primary immunization 500 mg rat IgV-MOG
22 Serum collection Boost with 500 mg rat IgV-MOG
36 Serum collection Boost with 500 mg rat IgV-MOG+500 mg macaca IgV-MOG
49 Serum collection Boost with 500 mg rat IgV-MOG+500 mg macaca IgV-MOG
63 Serum collection
93 Serum collection Boost with 500 mg rat IgV-MOG+500 mg macaca IgV-MOG
210 Serum collection
469 Serum collection
730 Serum collection
aThe immunization protocol was comprised of a primary immunization in IFA on day 0 followed by 4 booster immunizations in IFA on the designated days. On each
day, subcutaneous injections of rat and/or macaca IgV-MOG were given as 4 separate 100 ml injections (total volume of 400 ml) in the left and right groin and axilla.
These immunizations did not result in any visible signs of inflammation at the injection sites. Humane euthanasia was performed on Day 730.
doi:10.1371/journal.pone.0110048.t001
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immunization on day 0 with either 50 mg GP69-88 in CFA or
200 mg IgV-MOG in CFA on day 0 (Figure 2 & Table 2). One
GP69-88 immunized rat and one IgV-MOG immunized rat
reached a humane endpoint during the first episode of acute
classical EAE and thereafter were excluded from the remainder of
the experiment. Two IgV-MOG immunized rats developed
adjuvant arthritis on day 15 and 19 and were excluded from the
experiment. On day 28, rats that were given GP69-88 in CFA
were (n = 5) or were not (n = 6) boosted with 50 mg GP69-88 in
IFA. Rats that received IgV-MOG in CFA were (n = 4) or were
not (n = 5) boosted with 200 mg IgV-MOG in IFA. Rats
immunized with GP69-88 in CFA developed classical disease
marked by ascending paralysis and spontaneous recovery (Figur-
es 2A & 2B) whereas a subsequent boost of GP69-88 in IFA had
no clinical effect (Figure 2B). A single immunization with IgV-
MOG in CFA elicited a monophasic episode of classical EAE in 6
of 10 rats but no atypical EAE (Table 2 & Figures 2C–F). One of
these rats had severe classical EAE that necessitated humane
euthanasia (Figure 2C). After recovery, Lewis rats immunized with
IgV-MOG in CFA that were not re-challenged remained healthy
for the remainder of the experiment (Figure 2C). In contrast, IgV-
MOG/CFA immunized rats boosted with IgV-MOG in IFA
exhibited a course of atypical EAE (4 of 4 rats, Table 2). The
clinical courses of the 3 most severely afflicted rats are shown in
Figure 2D–F. One of these rats exhibited uncontrolled axial
rotation (Figure 2F) and was humanely euthanized. A 4th rat (not
shown) did not initially develop classical EAE via the first
immunization, but after the subsequent booster of rat IgV-MOG
in IFA, exhibited monophasic atypical disease from day 42 to 49
characterized by forelimb weakness, ataxia without tail paralysis,
and rigid asymmetrical limb extension (maximal score = 1.0). The
use of IFA for both IgV-MOG immunization and boosting did not
elicit EAE (data not shown). Overall, the main observation was
that after spontaneous remission from IgV-MOG/CFA-primed
classical EAE, a separate subsequent challenge with IgV-MOG/
IFA caused atypical EAE (Figure 2D–F) whereas the parallel
strategy did not elicit a relapse with GP69-88 (Figure 2B). These
findings provide a protocol to induce atypical EAE in Lewis rats.
The experiments shown in Figures 1–2 were repeated based on
a refinement of the IgV-MOG preparation method. For the IgV-
MOG preparation used in Figure 3, disulfide bridges in IgV-
MOG were reduced before the protein was refolded at low
concentrations to optimize intramolecular disulfide linkages and to
minimize intermolecular disulfide bridges. IgV-MOG contains a
single intramolecular disulfide bond. Previously, we noted that
during protein extraction and purification, oxidation introduced
abnormal crosslinking of IgV-MOG molecules via intermolecular
disulfide bonding at the expense of appropriate intra-chain
disulfide linkages. Lewis rats (female, n = 20, 8 weeks of age) were
immunized with 200 mg of monomeric rat IgV-MOG (n= 14) or
50 mg of GP69-88 (n= 6) in CFA on day 0 (Table 3 and Figure 3).
The same groups were respectively boosted with 200 mg of
monomeric rat IgV-MOG in IFA or 50 mg GP69-88 in IFA on
days 21 and 35. Rats were scored and weighed by a blinded
observer for clinical signs of EAE once per day before EAE onset
and twice per day after onset. Following a second boost of IgV-
MOG/IFA on day 35, the incidence of chronic atypical EAE was
92.3% (Table 3). One rat from this group had severe adjuvant
arthritis and was euthanized on day 22 prior to EAE development.
An additional rat did not exhibit signs of EAE throughout the
Figure 1. Booster immunizations with IgV-MOG in IFA caused a chronic course of atypical EAE. Seven Lewis rats were immunized with a
mixture of 25 mg of GP69-88 and 50 mg of rat IgV-MOG in CFA on day 0. After resolution of a classical monophasic bout of EAE, the same rats were
boosted with 200 mg of rat IgV-MOG in IFA on days 45 and 85. Rats were scored daily for clinical signs of EAE. After the IgV-MOG boosts in IFA, the
incidence of chronic atypical EAE was 100% (7 of 7 rats). The red arrows (bottom panel) mark the dates of the boosts. Shown are the individual
disease courses for the 7 rats. The blue line divides the clinical data into classical (left) and atypical (right) EAE courses.
doi:10.1371/journal.pone.0110048.g001
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experiment. Figure 3 depicts the clinical courses of atypical EAE
for the 12 symptomatic rats (Figure 3, A–L). The mean and
median day of onset was day 39.3 and 40, respectively. Figure 3M
(lane 4) shows a 15% SDS-PAGE gel of the protein preparation
used for immunization. Protein preparations before (lanes 1–2)
and after (lanes 3–4) TCEP reduction are shown under reducing
(lanes 1, 3) and non-reducing (lanes 2, 4) conditions. TCEP-HCl
was used to reduce all disulfide bonds before refolding of the
protein at low protein concentrations to optimize intra-chain
disulfide linkages. The use of TCEP-HCl to optimize intrachain
disulfide linkage in rat IgV-MOG is relevant to Tables 3–4 and
Figures 3, 4, 5, 6. Lane 4 of Figure 3M represents the folded,
native protein used for immunization, and Table 3 lists the
incidence of classical and atypical EAE for each group. Taken
together (Figures 1–3), these data indicate that rat IgV-MOG can
be used to reliably induce atypical EAE in Lewis rats by use of a
CFA immunization/IFA booster strategy.
Large confluent demyelinating lesions are predominant
in atypical EAE
Histological analyses of these rats (Figure 3) showed that
classical and atypical forms of EAE were associated with
qualitatively different types of inflammatory CNS lesions (Ta-
ble 4). Classical EAE was associated with numerous focal
inflammatory lesions. In contrast, atypical EAE was associated
with large confluent lesions marked by extensive demyelination
and by vacuolation (Figures 4, 5, 6). In both classical and atypical
disease, the majority of lesions were in the spinal cord (Figure 4)
and in the base of the brain stem (Figure 5). One rat with atypical
EAE also had an extensive cerebellar lesion (Figure 6). Healthy
rats were devoid of CNS lesions (Figures 4, 5, 6A, 4–6D) and had
normal myelination (Figure 4H). Figure 4 portrays representative
spinal cord sections. Classical EAE was associated with numerous
focal lesions (Figure 4B & 4E) and diffuse areas of demyelination
coincident with perivascular infiltration (compare Figures 4B &
4I). Atypical EAE was marked by confluent lesions encompassing
large areas of infiltration, vacuolation, and necrotic damage
(Figures 4C & 4F). These confluent lesions were marked by a
nearly complete absence of myelin (compare Figures 4C & 4J) and
the presence of large vacuoles. Confluent lesions often spanned
several longitudinal centimeters of spinal cord and were bilateral
or unilateral in regard to the width of the cord. Confluent lesions
were also noted for pathological changes in gray matter neurons
(not shown). The cauda equina appeared normal. Figure 5
portrays representative lesions in the brainstem. Again, classical
EAE was associated with focal inflammatory lesions (Figure 5B &
5E) whereas the brainstems of rats afflicted with atypical EAE all
had extensive confluent lesions (Figure 5C & 5F). Figure 6 shows
Table 2. Secondary responses to IgV-MOG elicited chronic atypical EAE in Lewis rats.
Immunization in CFAa Incidence during 1
st bout of EAE Boost in IFAa Incidence during 2
nd bout of EAE
Classical EAE Atypical EAE Classical EAE Atypical EAE
GP69-88 5 of 6 0 of 6 None 0 of 6 0 of 6
GP69-88 6 of 6 0 of 6 GP69-88 0 of 5 0 of 5
IgV-MOG 3 of 6 0 of 6 None 0 of 5 0 of 5
IgV-MOG 3 of 4 0 of 4 IgV-MOG 0 of 4 4 of 4
aLewis rats were immunized with 50 mg GP69-88 (n = 12) or 200 mg rat IgV-MOG (n = 12) in CFA on day 0. On day 28, GP69-88-immunized rats were (n = 5) or were not
(n = 6) boosted with 50 mg GP69-88 in IFA, and IgV-MOG-immunized rats were (n = 4) or were not (n = 5) boosted with 200 mg rat IgV-MOG in IFA. Rats were scored daily
for clinical signs of EAE. Classical and atypical EAE are defined in the Materials and Methods section.
doi:10.1371/journal.pone.0110048.t002
Figure 2. A CFA/IFA prime-boost strategy with IgV-MOG
elicited chronic atypical EAE in Lewis rats. Lewis rats were
immunized with either 50 mg of GP69-88 or 200 mg of rat IgV-MOG in
CFA on day 0. Rats were scored daily for clinical signs of EAE. On day 28,
GP69-88-immunized rats were or were not boosted with 50 mg of GP69-
88 in IFA. Conversely, rat IgV-MOG-immunized rats were or were not
boosted with 200 mg of rat IgV-MOG in IFA. Shown are overlapping
traces of disease courses of rats immunized with GP69-88 (A),
immunized with GP69-88 and given a subsequent boost (B), or
immunized with rat IgV-MOG without a subsequent boost (C). Also
shown are atypical disease courses of individual rats immunized and
boosted with rat IgV-MOG (D–F; 3 of 4 rats shown). Red arrows indicate
the booster immunization (B, D–F). The blue line divides the clinical
data into classical (left) and atypical (right) courses (D–F).
doi:10.1371/journal.pone.0110048.g002
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sections of the posterior brain and cerebellum. In classical EAE,
sparse focal lesions were seen in caudal brain (Figure 6B & 6F)
whereas the cerebellum lacked inflammatory lesions (Figures 6B &
6E). In one rat with atypical EAE, a large confluent lesion was
noted in the cerebellum (Figures 6C & 6G). In either classical or
atypical EAE, no lesions were noted in rostral brain regions. Initial
histological analysis of rats used in Figures 1–2 revealed evidence
for a greater lesion load in the rostral brain in atypical EAE
compared to classical EAE. However, such a difference in lesion
distribution was not evident for the analysis of rats shown in
Figure 3. Overall, these findings revealed a qualitative difference
in lesion type within the CNS of rats afflicted with classical versus
atypical EAE.
IgV-MOG induces atypical EAE in Macaca fascicularis
Given that IgV-MOG was pivotal for the induction of atypical
EAE in Lewis rats, a relevant question was whether a similar
strategy based on repeated boosting with IgV-MOG in IFA would
also elicit atypical EAE in NHP. We had one male cynomolgus
macaque available for this project. The cynomolgus macaque was
immunized with 500 mg of rat IgV-MOG and then four boosts of
either rat IgV-MOG alone or a combination of rat and macaca
IgV-MOG (Table 1). All antigen injections were in IFA. The
subject was directly observed once per day until disease onset and
then 3 times per day in ,30 minute sessions during overt disease.
The NHP exhibited a single episode of EAE with an onset on day
201 after the initial immunization and 108 days after the final
boost (Figure 7, Table 1).
On day 201, the onset of EAE was abrupt and was marked by
gross motor dyscoordination in both legs, including clumsy
ambulation and awkward movement about the enclosure, falling
to one side, use of arms to support walking and sitting, slow
deliberate and guarded movements, apparent sensory disturbanc-
es, lack of bilateral hand strength and finger dexterity, difficulty
climbing to the perch or reaching food at the top of the enclosure,
involuntary but transient balling of hand and foot, and repetitive
chomping motion in jaws. These clinical signs persisted with slight
improvement through day 207.
On days 208–215, the subject continued to show gross motor
dyscoordination, including a wobbly gait, use of the arms to brace
against the enclosure during ambulation, slow hesitant move-
ments, difficulty in climbing onto the perch or reaching the top of
the enclosure, occasional but substantial weakness on the right side
including the right leg, and continued difficulty with finger
dexterity. One of the distinct clinical signs that became apparent
during this period was a marked transient myotonia associated
with any sudden arousal, which was particularly evident at the
beginning of each observation period. These episodes of severe
disability transpired over 1–2 minutes and then were absent
during the remainder of the observation period. These episodes of
myotonia had variable presentation, including falling to one side,
gross motor dyscoordination during ambulation, rigid extension
paralysis of one leg or arm, and/or involuntary balling of a foot or
hand. Overall, the myotonic episodes resembled a neuromuscular
intention spasm of a brief duration followed by completely normal
function.
On days 216–221, the subject showed gradual improvement.
The main signs included slow deliberate but coordinated motion
punctuated by mild bouts of dyscoordination during ambulation.
Finger coordination was improved but not yet normal and was
associated with improved hand strength. The myotonic episodes
represented the most evident sign of disability. On days 222–242,
the major neurological disability included continued episodes of
arousal-induced frozen myotonia which gradually became less
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frequent, less severe, and of shorter duration. On days 243–247,
the subject exhibited mild, transient dyscoordination of hands and
feet but was otherwise normal. On day 248, the subject was scored
as normal (score of 0) and did not exhibit any additional signs of
disability to the end of the observation period at day 730.
Through the entire course of observation, the subject did not
exhibit flaccid paralysis or overt clinical signs consistent with
classical EAE such as progressive paralysis or an ascending flaccid
paralysis of the tail or hindlimbs. Nor did the subject show any
indication of hyperacute encephalitis as has been noted in other
NHP models of EAE [18–21,27].
Atypical EAE is associated with IgG specific for
extracellular, conformational epitopes of MOG
Atypical EAE in Lewis rats and the cynomolgus macaque was
associated with high titer Ab specific for extracellular, conforma-
tional epitopes of MOG (Figures 8, 9, 10, 11, 12). Fluorescence-
linked immunosorbent assays were used to measure serum Ab of
IgV-MOG immunized animals. Briefly, HEK were derived that
expressed full length rat MOG (rat MOG HEK) or full length
macaca MOG (macaca MOG HEK) with GFP. Rat and macaca
MOG HEK expressed GFP (Figures 8A & 8E, respectively) and
non-transfected HEK lacked GFP expression (Figure 8C & 8G,
respectively). Stably transfected HEK bound anti-MOG Ab in
immune serum, which was detected by fluorochrome-conjugated
secondary Ab against rat or macaque immunoglobulin. As shown
in Figure 8A & B, when incubated with an immune serum from
IgV-MOG sensitized Lewis rats, rat MOG HEK exhibited an
approximate 350-fold enhancement in relative mean fluorescent
intensity (MFI) compared to the same cells incubated with a non-
immune serum. Non-transfected HEK incubated with the
immune serum did not bind anti-MOG Ab (Figures 8C & 8D).
Similarly, macaca MOG HEK incubated with immune serum
from the IgV-MOG sensitized macaque exhibited 75-fold greater
MFI compared to the same cells treated with a non-immune
serum (Figures 8E & 8F, respectively). Non-transfected cells did
not bind the anti-MOG Ab from immune serum (Figures 8G &
8H, respectively). The rat immunization protocol was associated
with higher Ab titers (Figure 8B) compared to what was achieved
with the NHP protocol (Figure 8F). Overall, these studies showed
that immunization with IgV-MOG derived from a prokaryotic
expression system elicited high titer Ab that cross-reacted with full
length MOG on HEK. Thus, Ab against soluble non-glycosylated
Figure 3. Lewis rats immunized with intra-chain disulfide-linked IgV-MOG developed chronic atypical EAE. Female Lewis rats aged 8
weeks were immunized with 200 mg of rat IgV-MOG (n= 14) in CFA on day 0. These mice were boosted with 200 mg of rat IgV-MOG in IFA on days 21
and 35. Shown are the individual disease courses for the 12 symptomatic rats (A–L) that exhibited atypical EAE. All clinical data were scored based on
atypical scoring criteria. The red arrows (bottom panels) mark the dates of the boosts. Panel M shows the IgV-MOG protein preparation before TCEP
reduction (Lanes 1–2, reducing vs native SDS-PAGE, respectively) as well as IgV-MOG after TCEP reduction and refolding (Lanes 3–4, reducing vs
native SDS-PAGE). These clinical data are described in Table 3. Histological analyses are depicted in Figures 4–6 and Table 4.
doi:10.1371/journal.pone.0110048.g003
Table 4. Summary of CNS histological analyses.
Sensitizing
antigena
Incidence of
classical EAE
Incidence of
atypical EAE
Mean clinical
score
Predominant
lesion typeb
GP69-88 4 of 4 0 of 4 3.0 Focal
IgV-MOG 0 of 10 10 of 10 3.0 Confluent
aHistological assessment of classical EAE was assessed in 4 Lewis rats immunized with 50 mg GP69-88 in CFA. Histological assessment of atypical EAE was based on 10
Lewis rats immunized with 200 mg rat IgV-MOG in CFA and boosted with MOG-IgV/IFA on days 21 and 35. Rats were euthanized at peak disease.
bRepresentative sections are shown in Figures 4–6. In rats with classical EAE, approximately 100% of the lesion area in the CNS consisted of punctate areas of
mononuclear perivascular infiltration. In rats with atypical EAE, nearly 100% of the lesion area in the CNS was comprised of confluent lesions which were readily
discernable by the unaided eye on H&E sections as a dark blue in contrast to the light purple of surrounding normal tissue. Confluent lesions typically involved areas
greater than 1 mm2 and ranged from 1 mm to greater than 1 cm in one dimension, particularly in the spinal cord or at the base of the brainstem.
doi:10.1371/journal.pone.0110048.t004
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IgV-MOG cross-reacted with native glycosylated cell-surface
MOG proteins, presumably via shared conformational epitopes.
Humoral immunity to IgV-MOG in Lewis rats
Subsequent analyses showed that Lewis rats immunized and
boosted with IgV-MOG had high titers of anti-MOG Ab
compared to non-immunized naive rats (Figure 9). Immune serum
obtained from asymptomatic (Figure 9A, blue trace) and afflicted
(Figure 9A, red & green traces) rats 75 days after initial
sensitization showed similarly high levels of anti-MOG Ab. Lewis
rats immunized and boosted with IgV-MOG in IFA via an IFA-
IFA prime-boost strategy did not develop EAE, yet these rats also
produced anti-MOG Ab at titers similar to those in diseased rats
(Figure 9B). Together, these findings provide evidence that anti-
MOG Ab preceded disease development but were not sufficient to
Figure 4. Differential lesion histopathology in the spinal cords of rats afflicted with classical versus atypical EAE. Shown are
representative sections of the sacral spinal cord of rats that were healthy (A, D, H) or afflicted with either classical EAE (B, E, I) or atypical EAE (C, F, J).
Sections H–J show demyelination via Luxol Fast Blue stain. Red arrows highlight areas of confluent infiltration. Black arrows show focal perivascular
infiltration. Sections are from rats shown in Figure 3 and summarized in Tables 3–4.
doi:10.1371/journal.pone.0110048.g004
Figure 5. Differential lesion histopathology in the brainstem of rats afflicted with classical versus atypical EAE. Shown are
representative sections of the brainstem of rats that were healthy (A, D) or afflicted with either classical EAE (B, E) or atypical EAE (C, F). Red arrows
highlight areas of confluent infiltration. Black arrows show focal perivascular infiltration. Sections are from rats shown in Figure 3 and summarized in
Tables 3–4.
doi:10.1371/journal.pone.0110048.g005
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induce EAE. Serum collected from the same IgV-MOG/IFA-
immunized rats more than one year after the initial sensitization
showed essentially the same level of Ab binding (Figure 9B, shaded
traces) despite the absence of additional booster immunizations.
These data indicate the serum levels of anti-MOG Ab were
maintained over substantial periods of time.
Humoral immunity to IgV-MOG in a NHP
Immunization of the cynomolgus macaque resulted in a high
titer of anti-MOG Ab production as assessed by the fluorescence-
linked immunosorbent assay. Non-transfected HEK lacked
reactivity to all serum preparations tested (Figure 10A). Both rat
and macaca MOG HEK bound Ab in macaca immune serum
collected on days 36 and 49 but did not bind Ab in pre-
immunization serum collected on day 0 (Figures 10B & 10C).
Anti-rat MOG and anti-macaca MOG Ab titers increased
following a booster immunization with rat IgV-MOG on day 22
and the ‘‘rat IgV-MOG + macaca IgV MOG’’ immunization on
day 36 (Figures 10B & 10C). Macaca immune serum reacted
strongly with rat MOG (Figure 10B), and rat immune serum
reacted extensively with both rat MOG (Figure 10D) and macaca
MOG (Figure 10E). These data indicate that both rat and macaca
immune sera exhibited extensive cross-reactivity between the rat
and macaca MOG proteins. This extensive cross-reactivity was
consistent with the close homology of the two MOG species that
were distinguished by only 14 amino acid substitutions in the 123
amino acid span of the IgV domain.
To assess the isotype produced by the cynomolgus macaque,
non-transfected HEK (Figure 11A) or macaca MOG HEK
(Figures 11B–F) were incubated with macaque immune serum in
a primary incubation followed by a secondary incubation with
goat-anti-monkey IgG/M/A (Figures 11A& 11B), IgG (Figure 11C),
Figure 6. Differential lesion histopathology in the cerebellum of rats afflicted with classical versus atypical EAE. Shown are
representative sections of the hindbrain and cerebellum of rats that were healthy (A, D) or afflicted with either classical EAE (B, E–F) or atypical EAE (C,
G). Red arrows highlight confluent lesions. Black arrows show focal perivascular infiltration. Sections are from rats shown in Figure 3 and summarized
in Tables 3–4.
doi:10.1371/journal.pone.0110048.g006
Figure 7. Repeated booster immunizations of IgV-MOG in IFA caused an unusual form of EAE in a cynomolgus macaque. A
cynomolgus macaque was immunized with 500 mg rat IgV-MOG in IFA on days 0 and 22. Booster immunizations that consisted of a mixture of 500 mg
rat IgV-MOG and 500 mg macaca IgV-MOG in IFA were given on days 36, 63, and 93. Data represent the full time course of the experiment. After
recovery on day 248, the subject did not exhibit additional signs of EAE. Table 1 provides a timeline for the experimental approach.
doi:10.1371/journal.pone.0110048.g007
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IgM (Figure 11D), or IgA (Figure 11E). The results showed that the
cynomolgus macaque predominantly produced IgG Ab specific for
MOG (Figure 11C). Non-transfected cells did not bind Ab
(Figure 11A). The anti-MOG IgG signal was 300-fold greater than
the MFI values of controls lacking primary Ab. Anti-monkey IgM
and anti-monkey IgA revealed binding levels that were approxi-
mately 5-fold greater than negative control samples, but these
binding activities were apparent only in the day 36 and day 49 sera
and were absent in the day 63 serum (Figures 11D & 11E). Thus,
IgM and IgA anti-MOG Ab appeared transiently during the first
two months of immunization before the isotype of the humoral
response completely switched to IgG (compare Figure 11C &
Figures 11D–E). No additional boosters were given after day 93,
yet anti-MOG IgG Ab levels remained essentially constant in the
serum until day 730 at the end of the observational period
(Figure 11F).
The fluorescence-linked immunosorbent assay was not only
useful for the qualitative detection of anti-MOG IgG, the assay
was also useful for the quantitative measurement of relative anti-
MOG IgG titers (Figure 12). In the experiment represented by
Figure 12, a plate-based assay was used instead of a tube-based
assay (Figures 8, 9, 10, 11). A plate-based staining assay had two
main advantages; increased sensitivity for detection of anti-MOG
Ab and increased throughput for analysis of multiple samples. The
increased sensitivity for Ab-binding activity most likely reflected
faster processing time and more favorable dissociation/association
kinetics during washing due to decreased wash volumes. Each
wash for the tube assay represented an approximate 1/30 dilution
whereas each wash for the plate assay represented an approximate
J dilution. The plate assay enabled analysis of 96 samples in
approximately 20–30 minutes. Three distinct zones were noted in
assays that measured dilution of immune serum from a titration of
1023 to a titration of 1026 (i.e., 0.1 to 0.0001 on the x-axis)
including an antigen-excess zone, a saturable zone of equivalence,
and a prozone. From this bell-shaped curve, the antigen excess
zone provided an accurate measure of the amount of high affinity
IgG in the immune serum. These data revealed that half-maximal
binding was detected at a titration of approximately 1025 which
provides evidence of high titers of anti-MOG IgG. Saturable
binding was observed at titrations of 1023.5 to 1024.5 which most
likely reflected bivalent interactions of anti-MOG IgG with cell
surface MOG. A distinct prozone was noted at a titration of 1022.
The relative lack of signal at this titration may reflect competition
of anti-MOG IgG for a limited amount of cell surface MOG,
Figure 8. Flow cytometric assay of serum Ab specific for conformational epitopes of IgV-MOG. Rat MOG HEK (A–B), macaca MOG HEK (E–
F), or naive HEK (C–D, G–H) were incubated with (B, D, F, H) or without (A, C, E, G) anti-MOG immune serum, including rat anti-rat MOG immune
serum (B, D) or macaca immune antisera (F, H). The rat serum was from a rat primed with 200 mg IgV-MOG/CFA, boosted on day 25 with 200 mg IgV-
MOG/IFA, and drawn on day 36 when the rat was exhibiting clinical signs of atypical EAE including rigid hindlimb extension and forelimb weakness.
The macaca serum was obtained on day 36 as described in Table 1. After labeling with primary Ab, rat MOG HEK were washed and incubated with an
allophycocyanin-conjugated goat-anti-rat IgG/M secondary reagent, and macaca MOG HEK were washed and stained with an allophycocyanin-
conjugated goat-anti-monkey IgG/M/A Ab. The y-axis shows expression of GFP, and the x-axis represents the amount of anti-MOG Ab bound to the
HEK cell surface. Analyses were of individual serum samples, not pooled sera.
doi:10.1371/journal.pone.0110048.g008
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resulting in a preponderance of monovalent IgG interactions with
cell surface MOG. In this case, Ab bound via monovalent
interactions would predictably lack the avidity to remain bound
during the subsequent washes and may be lost by dissociation.
Alternatively, the prozone effect may be due to carryover of
soluble (non-bound) anti-MOG Ab from the first incubation.
Overall, these data showed that serum collected on day 0 and day
22 lacked anti-MOG IgG. After the first boost on day 22, the NHP
showed sero-conversion and had uniformly high titers of anti-
MOG IgG in all sera collected thereafter.
Discussion
This study has three lines of significance. First, we established a
novel and clinically significant model of atypical EAE in Lewis rats
(Figures 1, 2, 3). The model was robust in that the protocol elicited
severe paralytic signs. The model was reliable in that the incidence
of atypical EAE was usually 100% after one or two boosts with
IgV-MOG in IFA. The model was not complicated by a genetic
deficiency of the IFN-c pathway. This model should enable
development of novel therapeutics in a system that is mechanis-
tically unique from classical EAE. An optimal model would be
comprised of a primary immunization with 200 mg rat IgV-MOG
in CFA to elicit monophasic EAE, and after full recovery from
classical EAE, secondary booster immunizations with 200 mg IgV-
MOG in IFA on approximately days 21 and 35. Although we did
not systematically study the timing of the secondary immuniza-
tions, our view is that booster immunizations in this timeframe
would be optimal for a perspective of cost, expediency, and
practicality. The ability to test therapeutics in both atypical and
classical models of EAE may reveal therapeutics that could have
broad efficacy in mechanistically diverse forms of MS. Because
clinical expression of MS relapse seldom resembles classical EAE,
the atypical model may have special relevance for identifying
therapeutics that can modulate diverse forms of MS.
Second, the study provided evidence that this approach
(immunization of IgV-MOG in IFA) also has the potential to
elicit a complex neurological syndrome in a cynomolgus macaque
(Figure 7). The observation that the subject did not exhibit an
acute fatal disease or an ascending flaccid paralysis provided
suggestive evidence that this immunization protocol with macaca/
rat IgV-MOG in IFA may represent a suitable approach for
induction of a disease that more closely mimics MS than other
NHP models of EAE.
Third, the study revealed relationships among (a) immunization
with a non-inflammatory adjuvant (IFA rather than CFA)
(Figures 1, 2, 3, 7), (b) humoral immunity against conformationally
intact determinants of IgV-MOG (Figures 8, 9, 10, 11, 12), (c)
continuous confluent plaques of severe demyelination in spinal
cord and brainstem (Figures 4, 5, 6), and (d) a complex atypical
neurologic disease that more closely mimics the clinical heteroge-
neity of MS than the stereotypic ascending paralysis of classical
EAE. The association of the immunization strategy with anti-
MOG humoral immunity and atypical EAE were important in
both rat and macaca models of EAE. Indeed, the IFA boost
strategy of repeated IgV-MOG immunization resulted in high
titers of anti-MOG IgG, as tested by the fluorescent-linked
immunosorbent assay analyses in 100% of animals subjected to
this immunization protocol. Production of anti-MOG Ab preced-
ed onset of EAE and was invariably correlated with the presence of
EAE in all animals of this study. The presence of anti-MOG IgG
Figure 9. Lewis rats immunized with IgV-MOG developed Ab specific for conformational epitopes of MOG. (A) Lewis rats were
immunized with IgV-MOG in CFA, boosted with IgV-MOG in IFA, and sera were taken on day 75. Clinical courses of donor rats are shown in Figure 1
(numbered 1–7 top to bottom). Shown are GFP+-gated rat MOG HEK cells stained with: Black trace =normal rat serum; Blue trace = rat#2 with clinical
score of 0; Red trace = rat #1 with clinical score of 1.0; Green trace = rat #3 with score of 3.0. (B) Lewis rats were immunized with IgV-MOG in IFA via
the same antigens and schedule as designated for the NHP in Table 1. These rats (n = 3) did not exhibit clinically evident EAE. Shown are histograms
of GFP+-gated rat MOG HEK cells labeled with normal rat serum (black trace) or immune serum from two separate asymptomatic rats (red versus blue)
taken 442, 116, 416, and 93 days (top to bottom) after the day of immunization (DOI). Shaded traces indicate at least one year since DOI. Labeled cells
were detected with an allophycocyanin-conjugated secondary goat-anti-rat IgG/M secondary Ab. Analyses were of individual serum samples, not
pooled sera.
doi:10.1371/journal.pone.0110048.g009
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however was not sufficient for EAE because the IFA-IFA prime
boost strategy elicited high titer Ab but without EAE (Figure 9).
Conformational determinants of IgV-MOG may have a
special role in atypical EAE
Induction of humoral immunity against globular IgV-MOG
and use of a non-inflammatory adjuvant (IFA) represents a
rational experimental approach for initiation of atypical EAE.
Globular IgV-MOG is considered a substantially more potent B
cell immunogen than linear peptides of MOG because multivalent
B cell epitopes in the globular protein are all physically linked to
the intrinsic carrier T cell epitopes within the protein. Linear
peptides however may or may not contain a physically linked
carrier peptide. Thus, IgV-MOG would predictably drive a
greater diversity and frequency of B cell clones and thereby
stimulate a more potent humoral immune response against MOG.
The increased frequency of IgV-MOG specific B cells would
culminate in higher frequencies of MOG-specific B cell antigen
presenting cells (APC) and highly efficient B cell-mediated
presentation of MOG. In contrast to myeloid macrophage and
dendritic cell APC, B cells drive polarized Th2 cells and down-
regulate IFN-c dominated Th1 immunity particularly when the
immunogen is administered in IFA rather than CFA. As discussed
below, the lack of IFN-c is a critical variable favoring atypical
EAE.
Conformational determinants of IgV-MOG also have a special
role in the effector phase of EAE. Several studies showed that
autoreactive T cell-mediated CNS responses to MOG, myelin
basic protein, or other CNS myelin proteins act synergistically
with demyelinating Ab specific for conformational determinants of
MOG to cause extensive plaques of demyelination and aggravated
neurologic disease in rats [28–33]. T cell-mediated, myelin-specific
inflammation may not be sufficient to overtly cause neurologic
disease due to many factors such as inefficient T cell antigen
recognition or low CNS concentrations of the target antigen.
Thus, T cell-mediated responses may be sufficient for perivascular
infiltration of mononuclear cells but may lack the potency to drive
the continued invasion of the CNS parenchyma that is necessary
for severe paralysis. Nonetheless, subclinical perivascular infiltra-
tion of CNS-reactive T cells appears sufficient to cause permeation
of the blood brain barrier to enable diffusion of Ab and
complement into the CNS parenchyma. The binding of IgG to
native MOG on the surface of compact myelin is believed to fix
complement that in turn triggers the release of anaphylatoxins
followed by chemotactic migration and activation of polymorpho-
nuclear and mononuclear phagocytes that engulf opsonized
myelin in the CNS [34–37]. The consequence is phagocytosis of
opsonized myelin lamellae and axonal conduction deficits. Ab-
mediated demyelination is dependent upon recognition of
conformational determinants on the extracellular domain of
MOG, as opposed to recognition of linear continuous determi-
nants of MOG. That is, immunization with conformational MOG
epitopes is needed to elicit antibodies that are cross-reactive with
native transmembrane MOG in the CNS [38]. For this reason,
immunization with synthetic peptides of MOG is not pathogenic
and appears epiphenomenal to Ab-dependent models of EAE
because Ab against linear epitopes of MOG lack crossreactivity
with transmembrane MOG in the CNS.
Figure 10. Immunization of a cynomolgus macaque with IgV-MOG elicited Ab specific for conformational epitopes of MOG. Non-
transfected HEK (A), rat MOG HEK (B), or macaca MOG HEK (C) were stained with pre-immune serum (day 0 serum) or with macaca serum collected on
days 22, 36, or 49 as described in Table 1. Shown are GFP+ cells stained with the designated serum and an allophycocyanin-conjugated goat-anti-
monkey IgG/M/A Ab. Also shown are histograms of GFP+-gated rat MOG HEK (D) or macaca MOG HEK (E) cells stained with normal rat serum (blue
trace) or immune rat serum (filled red trace). The immune serum was from an IgV-MOG immunized Lewis rat exhibiting atypical EAE (i.e., rat #6 of
Figure 1 taken on day 103 with a score = 2.0). Ab binding was detected using an allophycocyanin-conjugated goat anti-rat IgG/M Ab.
doi:10.1371/journal.pone.0110048.g010
IgV-MOG Elicits Atypical EAE
PLOS ONE | www.plosone.org 13 October 2014 | Volume 9 | Issue 10 | e110048
Mouse and rat models of atypical EAE
Mouse models of ‘rotatory’ EAE are characterized by idiosyn-
cratic clinical signs qualitatively distinct from classical caudo-
rostral progression of flaccid paralysis [7–11]. Atypical disease is
also marked by an irregular disease progression, inter-mouse
heterogeneity in presentation of clinical signs, and in some cases, a
significantly delayed onset (,6 weeks) [11]. Interestingly, a given
encephalitogenic peptide induced either classical or atypical EAE
phenotypes in different mice of the same syngeneic cohort.
Currently, mouse models of atypical EAE lack the predictability of
the Lewis rat model and are therefore less suitable for the study of
therapeutics for MS. In contrast to these models, the rat model
described in Figures 1, 2, 3 and Tables 2–3 resulted in an atypical
disease with nearly 100% incidence.
The most reliable models of atypical EAE have been described
in IFN-c deficient mice. Balb/c mice deficient in the IFN-c
signaling pathway are more susceptible to atypical EAE induction,
yet mice within the same cohort exhibited different forms of
disease [8]. IFN-c receptor knockout mice show a similar
phenotype [39,40]. Atypical EAE, particularly in the absence of
IFN-c signaling, is associated with the presence of lesions in the
more rostral regions of the brainstem, cerebellum, and brain in
contrast to classical flaccid paralysis where lesions are more
concentrated in the caudal regions of the spinal cord [8,12]. These
studies highlight the dominant role of IFN-c in imposing classical
EAE over atypical EAE and indicate that a lack of IFN-c ‘allows’
atypical EAE. Thus, atypical EAE in IFN-c replete rodents may be
due to immunization strategies that cause strongly biased Th2
polarization and consequent down-regulation of IFN-c in the
context of chronic immune stimulation against MOG.
Figure 11. The isotype of the macaca anti-MOG Ab was IgG. Shown are GFP2 non-transfected HEK (A) or GFP+ macaca MOG HEK (B–F) that
were stained with macaca serum collected on days 0, 22, 36, 49, or 63 (A–E) and 93, 210, 469, or 730 (F) post-immunization as described in Table 1.
HEK were subsequently stained with an allophycocyanin-conjugated secondary Ab specific for macaca Ab isotypes, including anti-IgG/M/A (A–B),
anti-IgG (C, F), anti-IgM (D), anti-IgA (E).
doi:10.1371/journal.pone.0110048.g011
Figure 12. Anti-MOG IgG in macaca immune serum was a high-
titer Ab. Macaca MOG HEK were stained with designated titrations of
macaca serum (x-axis; 0.1 = 0.1% or 1/1000; 0.0001= 1/106) collected on
days 0, 22, 49, 63, or 93 (Table 1). A subsequent stain with an
allophycocyanin-conjugated anti-macaca IgG secondary reagent was
used to detect surface bound anti-MOG Ab.
doi:10.1371/journal.pone.0110048.g012
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Atypical EAE has also been observed in rats. Atypical EAE was
reported in a limited proportion of DA rats immunized with IgV-
MOG in IFA but not in CFA as indicated by the presence of
‘brain-stem’ demyelinating lesions and ataxia as the sole clinical
symptom [41]. Sporadic occurrence of atypical EAE was similarly
noted in some LEW.1AV1 rats immunized with rat IgV-MOG in
CFA as was evident as an uncontrolled body rotation [42].
Atypical EAE likewise occurred in LEW.N rats and several other
rat strains bearing the RT1n B/D MHC class II alleles upon
immunization with rat IgV-MOG in IFA as was noted by clinical
signs such as forelimb paralysis, severe balance disturbance, and
continuous rotatory spinning [43]. Aside from one study [42], an
atypical phenotype in rats was associated with the use of IFA
rather than CFA.
The IFA adjuvant, the antigen, and atypical EAE
The association of IFA-based booster immunizations with
atypical or non-classical EAE (Figures 1, 2, 3, 7) dovetails with
the association of the IFA adjuvant with Th2 or Th17 dominant
responses and a paucity of IFN-c production. The heat-killed
Mycobacterium component of CFA is known to prime Th1
responses and IFN-c production. In accordance, immunization of
various rat strains with rat IgV-MOG in CFA favored induction of
classical rather than atypical EAE [41,43]. Conversely, IFA may
elicit progressively less IFN-c production over time and a more
pronounced reactivity by alternative T cell subsets that may
promote atypical EAE. This concept is in accordance with our study
in that one or more boosters in IFA represented a key variable
needed for induction of atypical EAE in Lewis rats (Figures 1–2).
Antigen may regulate the balance between classical and atypical
EAE by an influence on APC preference. Although IgV-MOG in
IFA may initially elicit a weak Th1 response in Lewis rats, thereby
accounting for the initial self-limited bout of classical EAE, the
emergence of a strong humoral immune response may shift the
dominant APC subset from dendritic cells to IgV-MOG specific B
cells. Clonal expansion of antigen-specific B cells exponentially
increases the predominance of B cell APC because B cells use
antigen-specific surface immunoglobulin to capture antigen for
subsequent presentation. Emergence of IgV-MOG-specific B cells
as a predominant APC subset may in turn polarize the immune
response to alternative Th2 or Th17 responses and counter-
regulate Th1 T cell-mediated IFN-c production. In turn, lack of
IFN-c production may restrict access to various regions of the
CNS and thereby favor atypical EAE. Thus, a globular antigen
(IgV-MOG) that drives a vigorous polyclonal B cell response may
downregulate IFN-c production that enables predominance of the
type and distribution of lesions that favor atypical EAE.
Atypical EAE in a cynomolgus macaque
Three NHP models of EAE are prominent, including two in old
world species, Macaca fascicularis (cynomolgus macaques) and
Macaca mulatta (rhesus macaques), and one in a new world
species Callithrix jacchus (marmosets) [19,20]. Cynomolgus and
rhesus macaques are closely related, and the evolutionary span
between rhesus macaques and humans is approximately 35 million
years. Even specific mechanisms of cognate T cell antigen
recognition are cross-reactive between these primate species and
humans [21,44–48]. Marmosets are separated from humans by
approximately 55 million years in evolutionary time. The
Macaque species represent a primary choice for translational
research due to the close genetic link to humans.
These three species of NHP were tested for susceptibility to EAE
by repeated immunization with recombinant human MOG
protein (1–125 aa extracellular domain) in IFA adjuvant [49]. In
four cynomolgus macaques, 1–2 immunizations elicited a rapidly
progressive disease that reached the humane endpoint within
3 days. Another cynomolgus NHP had a monophasic course of
mild ataxic EAE with complete recovery but after a subsequent
booster exhibited paresis that progressed within 2 days to a
moribund state. CNS lesions in these NHP were often associated
with neutrophil infiltration, necrosis, hemorrhage, and demyelin-
ation. In two rhesus macaques, a primary immunization and one
boost caused a rapidly progressive disease that within two days of
onset caused complete paraplegia or quadriplegia in association
with large demyelinating plaques in brain including some
hemorrhagic lesions primarily populated with neutrophilic gran-
ulocytes. Two additional rhesus macaques that received four
immunizations however did not show clinical or histological EAE.
Marmosets, like the cynomolgus and rhesus macaques, also
exhibited a high incidence of an acute CNS demyelinating
syndrome that rapidly progressed in 3–9 days to reach humane
endpoints [49,50]. These experiments were based on the use of
MOG antigens in IFA but nonetheless resulted in a high incidence
of an acute paralysis reminiscent of classical EAE and were in
contrast to the mild monophasic disease course shown in Figure 7
of this study.
The differences in acute lethal EAE noted in [49] and the mild
monophasic disease (Figure 7) may be related to the several
considerations. First and most importantly, Figure 7 is based on a
single NHP that may not be representative of a larger cohort.
Second, we used a mix of rat and macaca IgV-MOG as opposed
to human IgV-MOG. Differences in antigenic strength therefore
may play a role in modulating disease, particularly in that ‘self’
determinants in the macaca IgV-MOG may engage regulatory T
cells to limit disease progression and impose tolerance to MOG.
Third, the folding, stability, and solubility of the IgV-MOG may
be an important but unpredictable variable. Our IgV-MOG
preparations were refolded from inclusion bodies and were soluble
but would develop aggregates at high concentrations. Aggregated
protein may have altered immunogenicity and may efficiently
elicit strong T cell-mediated responses via presentation by myeloid
APC. In contrast, soluble, natively-folded protein would more
likely be captured and presented by MOG-specific B cells and
therefore may more likely drive Th2 immunity and more complex
disease syndromes of atypical EAE. Natively folded, glycosylated,
highly soluble IgV-MOG monomers should be considered in
future studies of NHP-EAE in rhesus monkeys.
The transient, reversible, myotonias observed in the macaque
were reminiscent of an arousal-elicited episode of Uhthoff’s
phenomena, which is an abrupt, fully-reversible worsening of
neurological symptoms in MS of brief duration. Uhthoff’s attacks
are often triggered by increased body temperature, physical stress,
or psychological stress [51]. The macaque typically exhibited a
transient episode of rigid paralysis in a large limb or involuntary
balling of a hand or foot at the onset of an observation period,
particularly the third or evening observation period. These deficits
completely resolved in approximately 1–2 minutes. The sudden
arousal associated with the onset of the daily observation periods
appeared to elicit these episodes. Unlike classical EAE or
hyperacute EAE, the presence of complex neurological episodes
resembling the MS-associated Uhthoff’s syndrome in this atypical
macaca model of EAE reinforces the association of this case with
the complex neurological deficits of MS.
Conclusion
The present study revealed a new model of atypical EAE in
Lewis rats. This model represents an improvement over previously
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described rodent models of atypical EAE because the Lewis rat
model reliably exhibited a high incidence of severe atypical
disease. The study also provided a framework to study atypical/
complex EAE in Macaca fascicularis. Although the scope of the
NHP study was limited to one case, the disease had many
interesting features. The disease was self-limited, was stable, did
not progress to a humane endpoint, presented with complex
neurological signs, and was associated with robust IgG response
against conformational epitopes of macaca MOG. Notably, the
NHP case was not associated with an ascending flaccid paralysis or
other manifestations of classical EAE. Overall, the study showed
that repeated booster immunization with refolded globular IgV-
MOG in IFA is a key variable for induction of atypical or unusual
forms of EAE. Development of reliable atypical models of EAE is
an important goal for the field that will have important
implications for identifying valid MS drug candidates.
Acknowledgments
The authors would like to acknowledge Derek Abbott and Chris Jones for
their expert technical assistance, and Dr. Dianne Walters for use of her
microscopy laboratory.
Author Contributions
Conceived and designed the experiments: ADC NT RLW MRVS MDM.
Performed the experiments: ADC NT SPR EG RHR MDR RLWMRVS
MDM. Analyzed the data: ADC NT RLW MRVS MDM. Contributed
reagents/materials/analysis tools: ADC NT SPR EG RHR MDR RLW
MRVS MDM. Wrote the paper: ADC NT SPR EG RHR MDR RLW
MRVS MDM.
References
1. Lassmann H (2013) Pathology and disease mechanisms in different stages of
multiple sclerosis. J Neurol Sci 333: 1–4.
2. Geurts JJ, Barkhof F (2008) Grey matter pathology in multiple sclerosis. Lancet
Neurol 7: 841–851.
3. Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative
disorder? Annu Rev Neurosci 31: 247–269.
4. Simmons SB, Pierson ER, Lee SY, Goverman JM (2013) Modeling the
heterogeneity of multiple sclerosis in animals. Trends Immunol 34: 410–422.
5. Batoulis H, Recks MS, Addicks K, Kuerten S (2011) Experimental autoimmune
encephalomyelitis–achievements and prospective advances. APMIS 119: 819–
830.
6. Wekerle H (2008) Lessons from multiple sclerosis: models, concepts, observa-
tions. Ann Rheum Dis 67 Suppl 3: iii56–60.
7. Kroenke MA, Chensue SW, Segal BM (2010) EAE mediated by a non-IFN-
gamma/non-IL-17 pathway. Eur J Immunol 40: 2340–2348.
8. Abromson-Leeman S, Bronson R, Luo Y, Berman M, Leeman R, et al. (2004)
T-cell properties determine disease site, clinical presentation, and cellular
pathology of experimental autoimmune encephalomyelitis. Am J Pathol 165:
1519–1533.
9. Muller DM, Pender MP, Greer JM (2005) Blood-brain barrier disruption and
lesion localisation in experimental autoimmune encephalomyelitis with predom-
inant cerebellar and brainstem involvement. J Neuroimmunol 160: 162–169.
10. Muller DM, Pender MP, Greer JM (2000) A neuropathological analysis of
experimental autoimmune encephalomyelitis with predominant brain stem and
cerebellar involvement and differences between active and passive induction.
Acta Neuropathol 100: 174–182.
11. Kerlero de Rosbo N, Mendel I, Ben-Nun A (1995) Chronic relapsing
experimental autoimmune encephalomyelitis with a delayed onset and an
atypical clinical course, induced in PL/J mice by myelin oligodendrocyte
glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell
epitopes. Eur J Immunol 25: 985–993.
12. Wensky AK, Furtado GC, Marcondes MC, Chen S, Manfra D, et al. (2005)
IFN-gamma determines distinct clinical outcomes in autoimmune encephalo-
myelitis. J Immunol 174: 1416–1423.
13. Mannie M, Swanborg RH, Stepaniak JA (2009) Experimental autoimmune
encephalomyelitis in the rat. Curr Protoc Immunol Chapter 15: Unit 15 12.
14. Adelmann M, Wood J, Benzel I, Fiori P, Lassmann H, et al. (1995) The N-
terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces
acute demyelinating experimental autoimmune encephalomyelitis in the Lewis
rat. J Neuroimmunol 63: 17–27.
15. Mayer MC, Meinl E (2012) Glycoproteins as targets of autoantibodies in CNS
inflammation: MOG and more. Ther Adv Neurol Disord 5: 147–159.
16. Menge T, Lalive PH, von Budingen HC, Genain CP (2011) Conformational
epitopes of myelin oligodendrocyte glycoprotein are targets of potentially
pathogenic antibody responses in multiple sclerosis. J Neuroinflammation 8:
161.
17. Hart BAt, Laman JD, Bauer J, Blezer E, van Kooyk Y, et al. (2004) Modelling of
multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol 3:
588–597.
18. von Budingen HC, Hauser SL, Ouallet JC, Tanuma N, Menge T, et al. (2004)
Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein
differentially influences disease phenotype and antibody effector functions in
autoimmune demyelination. Eur J Immunol 34: 2072–2083.
19. t Hart BA, Bauer J, Brok HP, Amor S (2005) Non-human primate models of
experimental autoimmune encephalomyelitis: Variations on a theme. J Neur-
oimmunol 168: 1–12.
20. Brok HP, Bauer J, Jonker M, Blezer E, Amor S, et al. (2001) Non-human
primate models of multiple sclerosis. Immunol Rev 183: 173–185.
21. Kerlero de Rosbo N, Brok HP, Bauer J, Kaye JF, t Hart BA, et al. (2000) Rhesus
monkeys are highly susceptible to experimental autoimmune encephalomyelitis
induced by myelin oligodendrocyte glycoprotein: characterisation of immuno-
dominant T- and B-cell epitopes. J Neuroimmunol 110: 83–96.
22. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C (2001) T- and B-
cell responses to myelin oligodendrocyte glycoprotein in experimental
autoimmune encephalomyelitis and multiple sclerosis. Glia 36: 220–234.
23. Bettelli E (2007) Building different mouse models for human MS. Ann N Y A-
cad Sci 1103: 11–18.
24. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH (2005) Pathogenic
myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes
and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 102: 13992–
13997.
25. Oliver AR, Lyon GM, Ruddle NH (2003) Rat and human myelin
oligodendrocyte glycoproteins induce experimental autoimmune encephalomy-
elitis by different mechanisms in C57BL/6 mice. J Immunol 171: 462–468.
26. Mannie MD, Paterson PY, U’Prichard DC, Flouret G (1990) The N- and C-
terminal boundaries of myelin basic protein determinants required for
encephalitogenic and proliferative responses of Lewis rat T cells. J Neuroimmu-
nol 26: 201–211.
27. Massacesi L, Joshi N, Lee-Parritz D, Rombos A, Letvin NL, et al. (1992)
Experimental allergic encephalomyelitis in cynomolgus monkeys. Quantitation
of T cell responses in peripheral blood. J Clin Invest 90: 399–404.
28. Meeson AP, Piddlesden S, Morgan BP, Reynolds R (1994) The distribution of
inflammatory demyelinated lesions in the central nervous system of rats with
antibody-augmented demyelinating experimental allergic encephalomyelitis.
Exp Neurol 129: 299–310.
29. Linington C, Engelhardt B, Kapocs G, Lassman H (1992) Induction of
persistently demyelinated lesions in the rat following the repeated adoptive
transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmu-
nol 40: 219–224.
30. Fierz W, Heininger K, Schaefer B, Toyka KV, Linington C, et al. (1988)
Synergism in the pathogenesis of EAE induced by an MBP-specific T-cell line
and monoclonal antibodies to galactocerebroside or a myelin oligodendroglial
glycoprotein. Ann N Y Acad Sci 540: 360–363.
31. Lassmann H, Brunner C, Bradl M, Linington C (1988) Experimental allergic
encephalomyelitis: the balance between encephalitogenic T lymphocytes and
demyelinating antibodies determines size and structure of demyelinated lesions.
Acta Neuropathol 75: 566–576.
32. Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of
demyelination in rat acute allergic encephalomyelitis by circulating mouse
monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein.
Am J Pathol 130: 443–454.
33. Schluesener HJ, Sobel RA, Linington C, Weiner HL (1987) A monoclonal
antibody against a myelin oligodendrocyte glycoprotein induces relapses and
demyelination in central nervous system autoimmune disease. J Immunol 139:
4016–4021.
34. Hundgeburth LC, Wunsch M, Rovituso D, Recks MS, Addicks K, et al. (2013)
The complement system contributes to the pathology of experimental
autoimmune encephalomyelitis by triggering demyelination and modifying the
antigen-specific T and B cell response. Clin Immunol 146: 155–164.
35. Szalai AJ, Hu X, Adams JE, Barnum SR (2007) Complement in experimental
autoimmune encephalomyelitis revisited: C3 is required for development of
maximal disease. Mol Immunol 44: 3132–3136.
36. Tran GT, Hodgkinson SJ, Carter N, Killingsworth M, Spicer ST, et al. (2002)
Attenuation of experimental allergic encephalomyelitis in complement compo-
nent 6-deficient rats is associated with reduced complement C9 deposition, P-
selectin expression, and cellular infiltrate in spinal cords. J Immunol 168: 4293–
4300.
37. Nataf S, Carroll SL, Wetsel RA, Szalai AJ, Barnum SR (2000) Attenuation of
experimental autoimmune demyelination in complement-deficient mice. J Im-
munol 165: 5867–5873.
IgV-MOG Elicits Atypical EAE
PLOS ONE | www.plosone.org 16 October 2014 | Volume 9 | Issue 10 | e110048
38. Mathey E, Breithaupt C, Schubart AS, Linington C (2004) Commentary:
Sorting the wheat from the chaff: identifying demyelinating components of the
myelin oligodendrocyte glycoprotein (MOG)-specific autoantibody repertoire.
Eur J Immunol 34: 2065–2071.
39. Lee E, Chanamara S, Pleasure D, Soulika AM (2012) IFN-gamma signaling in
the central nervous system controls the course of experimental autoimmune
encephalomyelitis independently of the localization and composition of
inflammatory foci. J Neuroinflammation 9: 7.
40. Lees JR, Golumbek PT, Sim J, Dorsey D, Russell JH (2008) Regional CNS
responses to IFN-gamma determine lesion localization patterns during EAE
pathogenesis. J Exp Med 205: 2633–2642.
41. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, et al. (1998)
Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the
spectrum of multiple sclerosis pathology. Brain Pathol 8: 681–694.
42. Sakuma H, Kohyama K, Park IK, Miyakoshi A, Tanuma N, et al. (2004)
Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced
demyelinating disease in LEW.1AV1 rats. Brain 127: 2201–2213.
43. Muhallab S, Dahlman I, Wallstrom E (2005) Disparate MHC class II haplotypes
in myelin oligodendrocyte glycoprotein- and myelin basic protein-induced
experimental autoimmune encephalomyelitis. J Neuroimmunol 161: 155–161.
44. t Hart BA, Elferink DG, Drijfhout JW, Storm G, van Blooijs L, et al. (1997)
Liposome-mediated peptide loading of MHC-DR molecules in vivo. FEBS Lett
409: 91–95.
45. Meinl E, t Hart BA, Bontrop RE, Hoch RM, Iglesias A, et al. (1995) Activation
of a myelin basic protein-specific human T cell clone by antigen-presenting cells
from rhesus monkeys. Int Immunol 7: 1489–1495.
46. Geluk A, Elferink DG, Slierendregt BL, van Meijgaarden KE, de Vries RR, et
al. (1993) Evolutionary conservation of major histocompatibility complex-DR/
peptide/T cell interactions in primates. J Exp Med 177: 979–987.
47. Elferink BG, Geluk A, Otting N, Slierendregt BL, van Meijgaarden KE, et al.
(1993) The biologic importance of conserved major histocompatibility complex
class II motifs in primates. Hum Immunol 38: 201–205.
48. Bontrop RE, Elferink DG, Otting N, Jonker M, de Vries RR (1990) Major
histocompatibility complex class II-restricted antigen presentation across a
species barrier: conservation of restriction determinants in evolution. J Exp Med
172: 53–59.
49. Haanstra KG, Jagessar SA, Bauchet AL, Doussau M, Fovet CM, et al. (2013)
Induction of experimental autoimmune encephalomyelitis with recombinant
human myelin oligodendrocyte glycoprotein in Incomplete Freund’s Adjuvant in
three non-human primate species. J Neuroimmune Pharmacol.
50. Jagessar SA, Kap YS, Heijmans N, van Driel N, van Straalen L, et al. (2010)
Induction of progressive demyelinating autoimmune encephalomyelitis in
common marmoset monkeys using MOG34-56 peptide in incomplete freund
adjuvant. J Neuropathol Exp Neurol 69: 372–385.
51. Frohman TC, Davis SL, Beh S, Greenberg BM, Remington G, et al. (2013)
Uhthoff’s phenomena in MS–clinical features and pathophysiology. Nat Rev
Neurol 9: 535–540.
IgV-MOG Elicits Atypical EAE
PLOS ONE | www.plosone.org 17 October 2014 | Volume 9 | Issue 10 | e110048
